Postmenopausal Osteoporosis
📧 Sign up to get email alerts when something new happens for Postmenopausal Osteoporosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-01-05EMA Authorised: Junod (denosumab) — Gedeon Richter Plc.
EMA authorised Junod, a denosumab product from Gedeon Richter, for osteoporosis and postmenopausal osteoporosis.
-
FDA approval · 2025-12-19FDA Approved: BONCRESA — Original Application (Amneal Pharmaceuticals LLC)
The FDA approved BONCRESA (denosumab-mobz) from Amneal Pharmaceuticals LLC under an Original Application. It is indicated for conditions tre…
-
EMA approval · 2025-12-02EMA Authorised: Izamby (denosumab) — Mabxience Research SL
The EMA authorised Izamby (denosumab) for osteoporosis-related bone resorption disorders, including postmenopausal osteoporosis, with Mabxie…
-
EMA approval · 2025-11-27EMA Authorised: Rolcya (denosumab) — Sandoz GmbH
The EMA authorised Rolcya, a denosumab product by Sandoz GmbH, for osteoporosis including postmenopausal osteoporosis.
-
EMA approval · 2025-11-27EMA Authorised: Jubbonti (denosumab) — Sandoz GmbH
EMA authorised Jubbonti, a denosumab product from Sandoz GmbH, for osteoporosis and postmenopausal osteoporosis, reflecting its use in reduc…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2025-10-29FDA Approved: WYOST — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for WYOST (denosumab) submitted by Sandoz Inc, expanding the product's indications.
-
FDA approval · 2025-10-29FDA Approved: BILPREVDA — Original Application (Organon LLC)
The FDA approved Bilprevda (denosumab) from Organon LLC under an Original Biologics License Application. The product is approved for postmen…
-
FDA approval · 2025-10-29FDA Approved: ENOBY — Original Application (Hikma Pharmaceuticals USA Inc.)
FDA approved ENOBY (denosumab-qbde) from Hikma Pharmaceuticals USA Inc. via an original biologics license application. ENOBY is a denosumab …
-
EMA approval · 2025-10-22EMA Authorised: Prolia (denosumab) — Amgen Europe B.V.
The EMA authorised Prolia (denosumab) from Amgen Europe B.V. for osteoporosis, including postmenopausal osteoporosis. The decision date was …
-
FDA approval · 2025-10-15FDA Approved: ESTROGENS, CONJUGATED — Original Application (Ingenus Pharmaceuticals, LLC)
FDA approved a generic version of conjugated estrogens under an original ANDA from Ingenus Pharmaceuticals.
-
FDA approval · 2025-10-15FDA Approved: ESTROGENS, CONJUGATED — Original Application (Ingenus Pharmaceuticals, LLC)
FDA approved the original application for a generic conjugated estrogens product from Ingenus Pharmaceuticals, LLC, marking entry of this ge…
-
EMA approval · 2025-10-10EMA Authorised: Teriparatide Sun (teriparatide) — Sun Pharmaceutical Industries Europe B.V.
The EMA authorised Teriparatide Sun for osteoporosis, including postmenopausal osteoporosis.
-
EMA approval · 2025-10-09EMA Authorised: Zadenvi (denosumab) — Zentiva k.s.
EMA authorised Zadenvi (denosumab) for osteoporosis, including postmenopausal osteoporosis, with Zentiva k.s. as the marketing authorisation…
-
FDA approval · 2025-05-30FDA Approved: PROLIA — Supplemental Application (Amgen, Inc)
The FDA approved a supplemental application for PROLIA (denosumab) submitted by Amgen, authorizing changes to the drug's labeling. This acti…
-
EMA approval · 2025-05-20EMA Authorised: Conbriza (bazedoxifene) — Pfizer Europe MA EEIG
EMA authorised Conbriza (bazedoxifene) for postmenopausal osteoporosis. The marketing authorization holder is Pfizer Europe MA EEIG.
-
FDA approval · 2025-04-22FDA Approved: PREMPRO — Supplemental Application (Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.)
The FDA approved a supplemental application for Prempro (conjugated estrogens and medroxyprogesterone acetate) submitted by Wyeth/Pfizer to …
-
EMA approval · 2025-04-01EMA Authorised: Evista (raloxifene hydrochloride) — Substipharm
EMA has authorised Evista (raloxifene hydrochloride) for postmenopausal osteoporosis; the marketing authorisation holder is Substipharm.
-
FDA approval · 2025-03-28FDA Approved: TYMLOS — Supplemental Application (Radius Health, Inc.)
FDA approved a supplemental application for TYMLOS (abaloparatide) by Radius Health, Inc. The approval expands the product's labeling for os…
-
FDA approval · 2024-12-05FDA Approved: CALCITONIN SALMON — Original Application (Fresenius Kabi USA, LLC)
FDA approved Fresenius Kabi USA, LLC's Calcitonin Salmon as an original application (ANDA 212675), enabling the marketing of this generic ca…
-
FDA approval · 2024-11-06FDA Approved: TERIPARATIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva's supplemental application for Teriparatide (teriparatide), enabling marketing of a generic teriparatide product. This act…
-
FDA approval · 2024-10-23FDA Approved: ESTRADIOL — Original Application (ANI Pharmaceuticals, Inc.)
The FDA approved ANI Pharmaceuticals' generic estradiol product under an original application.
-
FDA approval · 2024-09-27FDA Approved: ALENDRONATE SODIUM — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for ALENDRONATE SODIUM by Aurobindo Pharma Limited (generic).
-
EMA approval · 2024-09-16EMA Authorised: Bonviva (ibandronic acid) — Atnahs Pharma Netherlands B.V.
The EMA authorised Bonviva (ibandronic acid) for osteoporosis, including postmenopausal osteoporosis. The marketing authorization holder is …
-
FDA approval · 2024-08-26FDA Approved: ESTRADIOL — Supplemental Application (Zydus Pharmaceuticals USA Inc.)
FDA approved a supplemental application for Estradiol by Zydus Pharmaceuticals USA Inc., associated with the generic product's approval upda…
-
FDA approval · 2024-08-02FDA Approved: LYLLANA — Supplemental Application (Amneal Pharmaceuticals LLC)
FDA approved a supplemental application for LYLLANA (estradiol) submitted by Amneal Pharmaceuticals LLC.